RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
202 hedge funds and large institutions have $3.05B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2020 Q4 according to their latest regulatory filings, with 49 funds opening new positions, 69 increasing their positions, 65 reducing their positions, and 32 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
6% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 65
60% less call options, than puts
Call options by funds: $17.8M | Put options by funds: $44.5M
Holders
202
Holding in Top 10
9
Calls
$17.8M
Puts
$44.5M
Top Buyers
| 1 | +$150M | |
| 2 | +$44M | |
| 3 | +$27.8M | |
| 4 |
DFO
Duquesne Family Office
New York
|
+$25.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$25.5M |
Top Sellers
| 1 | -$20.6M | |
| 2 | -$15.9M | |
| 3 | -$15.8M | |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$14.3M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$12.7M |